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Abstract 
A major disease of the retina is age related macular degeneration, or ARMD. In this 
disease, the photoreceptor cells die and blindness results. Lutein and zeaxanthin, two 
carotenoids highly concentrated in the macular area, are thought to help protect against 
ARMD. Supplementation has been shown to raise macular pigment levels of lutein. It is 
proposed that Ocuvite (Bausch & Lomb) supplementation, which is a preparation of 
lutein plus other antioxidant molecules, will increase the macular pigment density of 
lutein and zeaxanthin. This study had forty-eight optometry students, twenty-four male 
and twenty-four female, who were divided into two groups. Group one, the control 
group, received no intervention. Group two, the experimental group, received one tablet 
of lutein daily for six months. Heterochromic flicker photometry, a psychophysical 
technique, was used to measure the macular pigment density level over a seven-month 
period. The macular pigment density level was assessed at baseline before any 
intervention, and then approximately every month for six months. Lutein did not 
significantly increase macular pigment density levels over a six-month period in the 
experimental group versus the control group. 
Introduction 
The leading cause ofvisual impairment and blindness of people over 60 years of 
age in Western countries is age-related macular degeneration (AMD). Incidence of AMD 
is expected to increase due to the increase in the population of those over 65 years of age. 
There are two forms of AMD: dry (atrophic) and wet (neovascular). Dry AMD is the 
precursor of the more serious wet form. Oxidative damage due to free radical formation 
is thought to cause AMD. Blue light entering the eye causes free radical formation in the 
photoreceptor outer segments. The free radicals damage the disc membranes here; this 
damage prevents the digestion of the discs after they are phagocytized by the RPE. Disc 
membranes accumulate in the RPE forming lipofuscin and are also deposited in in 
Bruch' s membrane as drusen. With increasing damage, RPE cells, and subsequently 
photoreceptors, die. 
Several significant risk factors for AMD have been identified. Persons with light 
irides (9), those with family history of AMD, and smokers (11) are known to be at a 
higher risk of AMD than the general population. Other contributing factors include age, 
diabetes, hypertension, and atherosclerosis. 
While the progression of wet AMD can be slowed or halted with laser 
photocoagulation and photodynamic therapy, the dry form currently has no accepted 
treatment. Because of this, recent efforts have concentrated on preventing the damage 
that causes AMD. Much research has focused on nutrition, especially antioxidants and 
carotenoids (1, 4, 7, 8, 10, 12, 16, 19, 20, 23, 27, 28, 29, 31). Lutein and zeaxanthin are 
two fat-soluble xanthophyll pigments that are classified as carotenoids (14). They are 
found selectively in the retina, with the highest concentrations in the macular area, and 
are classified as macular pigments. Both lutein and zeaxanthin appear to have a critical 
role in macular health, and have been shown to reduce the risk of developing AMD (3, 
27, 28). In the retina, lutein can be converted to zeaxanthin. Because these molecules 
lie between the incoming light and the macular cones and because they are yellow, they 
act as a filter to reduce oxidizing blue light from reaching the cones (and rods) in the 
macular area. These two molecules also have antioxidant properties. They can quench 
free radicals by donating electrons without themselves becoming f!ee radicals. Through 
this antioxidant and/or filter effect, lutein and zeaxanthin are thought to protect macular 
cones from oxidation and thus protect the retina from age-related macular degeneration. 
Lutein and zeaxanthin are not produced in the body. They must be obtained from the 
diet. Foods rich in these carotenoids include dark green leafy vegetables, yellow 
vegetables, egg yolks, and fruits such as grapes and kiwi fruit (27, 30). Supplementation 
with lutein and/or increased dietary intake of lutein and zeaxanthin have been shown to 
raise these macular pigment levels (4, 7, 10, 13, 16). 
Macular pigment density can be measured by heterochromic flicker photometry 
(HFP) (16). In this technique, blue and green lights flicker in counter-phase, and the 
subject is asked to match the brightness of two lights. Brightness match is determined 
when the lights are presented to the macula and again when they are presented in the 
retinal periphery where the concentration of lutein and zeaxanthin is low. The match 
value for the peripheral retina provides an indication of relative absorbencies ofblue and 
green lights by the media of the eye exclusive of the macular pigment, and the match for 
macular stimulation indicates the absorbance of the media plus the macular pigment. The 
difference in the macular and peripheral match values indicates the macular pigment 
density. 
Though it has been shown that diets rich in foods containing lutein and zeaxanthin 
increase macular pigment levels and thus reduce risk of macular degeneration, results of 
various studies are inconsistent. It is generally accepted that there is an associative 
relationship between lutein and zeaxanthin intake and AMD, but a preventative link is 
still in question (20). Further research is necessary to prove this. 
This study evaluated macular pigment density in young healthy participants. 
Macular pigment density was measured, using HFP, monthly for six months in two 
randomized groups of participants: one group taking Ocuvite with Lutein (Bausch & 
Lomb) daily, and one group taking no supplement. 
Method 
Participants 
Forty-eight participants, all optometry students, were involved in this study. 
Twenty-four were females and twenty-four were males ranging from 21 to 30 years in 
age. All participants were screened (Appendix A) and had good ocular and systemic 
health. Participants were randomly divided into 2 groups: a control group who received 
no intervention, and an experimental group who took one lutein supplement ( 6 mg) a day 
for 6 months. 
Supplementation 
The lutein supplements that we used were Bausch and Lomb Ocuvite tablets 
containing 6 mg of lutein. Participants in this group took one capsule per day. Before 
the onset of the experiment, intake of lutein was gathered from all participants using a 
questionnaire. Participants were asked if they were currently taking vitamins and if they 
were taking vitamins, if they contained lutein. 
Measurement of Macular Pigment Density 
Macular pigment density was measured using heterochromic flicker photometry. 
The optical system for this technique is illustrated in Appendix B. A xenon arc source 
was divided into three beams by a beam splitter and front surface mirror. Neutral density 
filters control the amount of light passing through the system. Interference filters 
produce the desired wavelength of 460 nm for the measuring field and background field, 
and 550 nm for the reference field. Apertures were used to concentrate both the reference 
field and measuring field to subtend one degree, and the background field to subtend ten 
degrees. A rotating sectored wheel produces the flickering test stimulus by alternating 
the transmission of the measuring field and reference field. The three fields were 
combined into one field through the use of beam splitters and a front surface mirror, and 
the combined image of all three apertures was placed at the subject's pupil by an 
achromatizing lens. 
Minimal flicker was achieved at 5.5 degrees from the macula, where macular 
pigment is optically undetectable, by adjusting the luminance ofthe measuring field. The 
target was then presented at the macula and participants readjusted the luminance of the 
measuring field with a variable density beam splitter to achieve minimum flicker. 
Macular pigment measures were based on the difference in neutral density filter used in 
the periphery to the neutral density filter used at the macula when minimal flicker was 
achieved. Multiple measures were taken on each eye for both macular and perimacular 
positions. Macular pigment measures are expressed in equivalent terms of neutral 
density filters. 
Two baseline measurements were taken during week one of the study before 
participants began taking the supplement. After the baseline measurement, one 
measurement was taken approximately one month apart for the next six months. 
Results 
Macular pigment density (MPD) at baseline, is shown in Table 1. Repeated-
measures analysis of variance (ANOVA) was used to compare the control and 
supplement groups. There is a significant difference in MPD between the two groups 
throughout the study, F(l, 43) = 8.37, p = 0.006. 
ANOVA was also used as a comparison across trials (seven measurements per 
group). There is no significant change in MPD across the seven-month measurement 
period, without regard to the study group, F(6, 258) = 1.01, p = 0.422. 
ANOV A was used to look at the interaction effect of groups and trials. There is 
no significant rate of change in MPD between the two groups, F(6, 258) = 1.05, p = 
0.396. 
Table 1. Macular Pigment Density at Baseline 
Study Group Number of Mean Standard Deviation 
participants 
Control Group 24 0.78 0.390 
Supplement Group 21 0.99 0.454 
Discussion 
This study showed no significant differences in macular pigment density over 
time between a group of young subjects using lutein supplementation versus a similar 
group using no supplementation. There are studies, however, that do show a correlation 
between lutein supplementation and macular pigment density. 
Previous studies have found that people with greater concentrations of the 
carotenoids, lutein and zeaxanthin, have lower rates of AMD (3,27,28). Since lutein can 
be converted into zeaxanthin in the retina, it is an essential carotenoid that must somehow 
be obtained through the diet. 
Literature shows that macular pigment density decreases with age. It is 
particularly important then for elderly patients to take supplements or increase dietary 
intake of these carotenoids. A similar study using elderly participants should be 
considered. Another consideration should be the amount of lutein supplemented. While 
6 mg a day might produce a change in an elderly patient, if younger people are going to 
participate, an increased amount of lutein should be considered. 
Macular pigment density determination is a difficult process. Participants 
consistently reported having a very hard time distinguishing flicker. This may be 
attributed to the age of participants or to the procedure ofHFP. Another method of 
measurement may be more reliable. 
This study showed no significant results in changes of macular pigment density. 
There are studies, however, that do show a correlation between supplementation and 
macular pigment density. At this time it is recommended that all people with risk factors 
for AMD use supplements containing lutein and zeaxanthin. 
Appen.it'x A 
Participant Name:--------------------------
Address: 
----------------------- --------
Phone number: 
--------------------- ------
Email: 
--------------- -----------------Age: ___ _ 
Case History: 
Do you have any history of ocular disease? Yes No 
If yes, what kind? ---------------------------
Do any of your parents or relatives have any history of age related macular degeneration? 
Do you or any of your relatives have any history of cataracts? ______ ___ _ 
Do you smoke? Yes No 
Do you take any vitamin supplements? Yes 
No 
No 
If so, do they contain Lutein? Yes 
Visual Acuities: 
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FigtAr-e 1. 
Optical system fo r measuring macular pigment density 
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